New York State Common Retirement Fund Boosts Stake in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)

New York State Common Retirement Fund raised its holdings in shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 19.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 39,399 shares of the specialty pharmaceutical company’s stock after acquiring an additional 6,491 shares during the period. New York State Common Retirement Fund owned approximately 0.14% of Paratek Pharmaceuticals worth $950,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. C WorldWide Group Holding A S boosted its stake in Paratek Pharmaceuticals by 449.3% in the 2nd quarter. C WorldWide Group Holding A S now owns 439,400 shares of the specialty pharmaceutical company’s stock worth $10,590,000 after purchasing an additional 359,400 shares during the period. Pictet Asset Management Ltd. bought a new stake in Paratek Pharmaceuticals during the 2nd quarter worth about $6,957,000. Renaissance Technologies LLC lifted its position in Paratek Pharmaceuticals by 275.9% during the 1st quarter. Renaissance Technologies LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock worth $7,979,000 after buying an additional 304,249 shares in the last quarter. Franklin Resources Inc. lifted its position in Paratek Pharmaceuticals by 106.8% during the 2nd quarter. Franklin Resources Inc. now owns 508,066 shares of the specialty pharmaceutical company’s stock worth $12,244,000 after buying an additional 262,374 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Paratek Pharmaceuticals by 1,898.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 199,725 shares of the specialty pharmaceutical company’s stock worth $4,813,000 after buying an additional 189,730 shares in the last quarter. Institutional investors own 82.46% of the company’s stock.

A number of brokerages have recently issued reports on PRTK. HC Wainwright upped their target price on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a report on Tuesday, July 18th. Cantor Fitzgerald set a $50.00 target price on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, July 17th. Zacks Investment Research lowered shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. ValuEngine lowered shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. Finally, Raymond James Financial, Inc. restated a “strong-buy” rating and issued a $36.00 target price on shares of Paratek Pharmaceuticals in a research report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $40.00.

WARNING: “New York State Common Retirement Fund Boosts Stake in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)” was first posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.truebluetribune.com/2017/11/14/new-york-state-common-retirement-fund-has-950000-position-in-paratek-pharmaceuticals-inc-prtk.html.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) opened at $21.65 on Tuesday. Paratek Pharmaceuticals, Inc. has a twelve month low of $12.55 and a twelve month high of $29.00. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply